Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 3/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478183 | 0.94 | PTPN1 (0.66) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL11137241 | 0.86 | PTPN1 (0.57) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL31279403 | 0.86 | HPGD (0.64) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL10389933 | 0.84 | SMN1; SMN2 (0.83) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL21834400 | 0.84 | DHODH (0.53) | MAPTSMN1; SMN2L3MBTL1CES2ALDH1A1 | |
| SCHEMBL4831377 | 0.83 | HTR7 (0.60) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL11139436 | 0.82 | PTPN1 (0.60) | MAPTPTPN1GSK3BCES2CES1 | |
| SCHEMBL11138890 | 0.80 | PTPN1 (0.54) | MAPTSMN1; SMN2L3MBTL1PTPN1GSK3B | |
| SCHEMBL6602154 | 0.80 | PTPN1 (0.62) | MAPTPTPN1GSK3BCES2CES1 | |
| SCHEMBL28098469 | 0.80 | CES2 (0.59) | MAPTSMN1; SMN2L3MBTL1CES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103298344-A | Integrin-linked kinase inhibitors | UNIV OHIO STATE RES FOUND | 2013-09-11 | — | — | CN | disclosed |
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | MAPT 4731/4885SMN1; SMN2 3242/4885L3MBTL1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.